Gamunex-c 20 gram/200 ML vial 200ML
Ended Awarded Last action
- Contract number
- SPE2DR26F9X86
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $57,052
Award facts
- Contract value 100% obligated
- $57,052.32 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $57,052.32 to AmerisourceBergen Drug Corp for the procurement of Gamunex-C (20 gram/200 mL vial, 200 mL units). This firm fixed-price contract, awarded January 15, 2026, with completion targeted for February 6, 2026, represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical. The underlying IDC, valued at up to $999,999,999.00 and extending through December 2031, serves as a comprehensive pharmaceutical supply vehicle supporting military healthcare programs globally. This award was competitively awarded with no set-aside designation, demonstrating the contractor's capability to meet federal procurement requirements in open competition.
Gamunex-C is an intravenous immunoglobulin (IVIG) therapy used to treat various immune-mediated conditions affecting military service members and beneficiaries within the defense healthcare system. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, functions as a critical vendor within the federal medical supply chain, delivering a diverse portfolio of pharmaceutical products including specialty medications, vaccines, and medical supplies across multiple therapeutic domains. The company's role as a prime pharmaceutical distributor enables DLA to efficiently source essential immunological treatments and other medical commodities required by military treatment facilities and veteran healthcare programs.
Quick answers
Who was awarded contract SPE2DR26F9X86?
SPE2DR26F9X86 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 15, 2026.
How much is contract SPE2DR26F9X86 worth?
The government has obligated $57,052 on SPE2DR26F9X86.
Is contract SPE2DR26F9X86 an order under another contract?
Yes. SPE2DR26F9X86 is a delivery order under SPE2DR25D3103, an indefinite delivery contract.
Was contract SPE2DR26F9X86 competed?
The extent of competition for SPE2DR26F9X86 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award